SBIR/STTR Research Award

OncoPath: Intelligent Clinical Pathway Decision Support Tool for Pre-Authorization Documentation in Non-Small Cell Lung Cancer Treatment

Award identifier a523f64cb9d5fc235e0400d9b30e057a64917cf5f0cd9c8dc07c2537ac5e0069Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$398,721

Program and phase

SBIR · Phase I

Award year

2021

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
VIZLITICS INC
Proposal award date
2021-09-01
Contract end date
2022-08-31
UEI
N1EMHHVX3F35
Solicitation number
PA20-260
Topic code
102

Research abstract

Project Abstract In a real-world clinical setting, busy oncologists lack the time for investigative case analysis across all feasible treatment options, frequently updated treatment guidelines and payor specific requirements. This results in sub- optimal decision making, incomplete pre-authorization (pre-auth) documentation, and problems with reimbursement. Overall, this increases medical costs and payment deficits within oncology. For example, pre- auth inefficiencies are estimated to add $83,000 a year per physician to healthcare costs, which is $1.1 billion annually in oncology alone. To devise a treatment plan, oncologists reference National Comprehensive Cancer Network Guidelines® (NCCN), other clinical society standards, and payor specific requirements in the context of a patient’s medical history, tumor characteristics, and phase of treatment. One of the most used oncology treatment guidelines referenced by oncologists and adhered to by most payors is the National Comprehensive Cancer Network (NCCN) Guidelines®. These guidelines are presented as a schema that span 100s of pages.A technology driven clinical decision support (CDS) system could be employed to address the need to streamline treatment guideline analysis, payor rules review, and treatment decision documentation for reduced overall cost to oncology practices. This proposal focuses on developing an innovative and first-of- a-kind technology for CDS using non-small cell lung cancer (NSCLC) as the initial test case and incorporating NCCN Guidelines, general payor specific requirements and patient data overlaid to compute feasible treatment pathways. The team proposes the following Phase I Specific Aims: Aim 1: Develop a graph-based mathematical model and visual presentation of NSCLC NCCN treatment guidelines with generalized payor specific requirements. Develop a visually interactive graph-based representation of NCCN Guidelines®. Modeling guidelines as a visual graph (nodes and arcs) will enable oncologists to identify the optimal treatment pathway for their patients. Aim 2: Build an analytics engine that highlights the NCCN graph model with feasible treatment options given the patient’s case details and common payor requirements. Use an opensource tool to create synthetic patient data and common payor constraints with an oncologist and health plan experts. Develop a library of graph traversal algorithms to overlay and visualize the patient data in a visual user interface. Aim 3: Execute, validate and test a proof-of-concept CDS workflow using OncoPath. Run the complete end-to-end CDS workflow with documentation of patient details, NCCN guideline, payor requirements and treatment decision using synthetic patient data and payor constraints generated in Aim 2.OncoPath will enable an efficient, oncologist-friendly approach to treatment decisions and documentation, subsequently benefitting the patient and decreasing oncology cost. Phase II will deploy a real-time instance of OncoPath in a single thoracic oncology practice for integrated workflow and time savings validation.Project Narrative In a real-world clinical setting, busy oncologists lack the time for investigative case analysis across all feasible treatment options, frequently updated treatment guidelines and payor specific requirements. This results in sub-optimal decision making, incomplete pre-authorization (pre-auth) documentation, and problems with reimbursement. Overall, this increases medical costs and payment deficits within oncology. To address this unmet need, this proposal aims to build OncoPath, a prototype tool in non-small cell lung cancer providing a first-of-a-kind visual representation of the NCCN Guidelines® with patient data overlaid to easily review, select, and document the patient information, treatment selection with NCCN supporting evidence, payor constraints, and any clinical narrative.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

4 SBIR/STTR records share this UEI (2021–2025). Reported award amounts total $4,065,183. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.